Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Multiple Myeloma 187Lymphoma, Mantle-Cell 34Neoplasms, Plasma Cell 32Lymphoma 32Recurrence 26Lymphoma, Follicular 20Waldenstrom Macroglobulinemia 18Lymphoma, Non-Hodgkin 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Carcinoma, Non-Small-Cell Lung 13Immunoglobulin Light-chain Amyloidosis 10Neoplasms 9Leukemia, Myeloid, Acute 9Lymphoma, B-Cell 8Renal Insufficiency 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Hodgkin Disease 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Brain Neoplasms 4Amyloidosis 4Stomach Neoplasms 3

Interventions

Docetaxel 137Prednisone 120Abiraterone Acetate 91Leuprolide 86enzalutamide 84Radiotherapy 59bicalutamide 56Magnetic Resonance Spectroscopy 54Goserelin 54Androgen Antagonists 51acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 47apalutamide 44abiraterone 34Radiosurgery 31Specimen Handling 30gallium 68 PSMA-11 29Gonadotropin-Releasing Hormone 29cabazitaxel 28Carboplatin 27darolutamide 25Estramustine 24luprolide acetate gel depot 23relugolix 22Metformin 22Triptorelin Pamoate 20sipuleucel-T 19radium Ra 223 dichloride 19Radiation 19pembrolizumab 18deltacortene 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Prostatic Neoplasms × Bortezomib × Clear all
NCT00183937 2026-05-15

Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

University of Southern California

Phase 2 Terminated
15 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT00103376 2018-11-05

Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Medical University of South Carolina

Phase 2 Terminated
23 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT00425503 2014-04-21

PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

Baylor College of Medicine

Phase 2 Completed
40 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT00193232 2010-07-28

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

SCRI Development Innovations, LLC

Phase 2 Completed
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡